News & Analysis on Clinical Trial Services & Contract Research And Development
Procter & Gamble (P&G) has announced its intention to outsource the active pharmaceutical ingredient (API) R&D and manufacturing work undertaken at one of its US factories, with resultant closure of the site and job losses.
Orphan drug Soliris (eculizumab) has been approved by the European Commission and marks the first therapy for a rare and life-threatening blood disease.
Asterand said it is to slash 10 per cent of its total workforce in a cost-cutting strategy although it is not a knock-on effect of the recent ban on export of human samples from Russia.
A new class of diabetes drugs is showing promising clinical results, with the big players in the field all scrapping it out for a slice of the potential rewards.
With a number of companies competing in the race to develop the first oral treatment option for multiple sclerosis, UCB and Biogen Idec's oral version of the infamous Tysabri has entered Phase II trials.
Six months after a couple of failed Phase III trials, Nuvelo has reinstated clinical development for its blood clot dissolving drug, but it will have to go it alone after Bayer decided enough is enough and pulled out of the collaboration.
A new living cell-based skin graft technology is being hailed by its inventors as a 'clinical breakthrough in regenerative medicine' following early-stage trial results, published yesterday.
Pfizer has had its first day in a Nigerian court in a legal dispute over its alleged involvement in the death of Nigerian children during a clinical trial 11 years ago.
PTC Therapeutics, Encysive, Novagali Pharma and Insmed have all had people on the move in the world of pharmaceutical manufacturing.
SkyePharma's novel controlled-release sleep therapeutic has been licensed by Somnus Therapeutics in an exclusive worldwide development and commercialisation deal.